PARP Inhibition
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
... Large areas of chromosomal loss that have been pre- viously identi fi ed in myeloma, e.g. del[1p], del[13q] are well recognized and have been associated with adverse outcomes [15, 16]. Smaller regions of loss across the ...
6
Prospects for combining immune checkpoint blockade with PARP inhibition
... additional PARP inhibition could alleviate resistance and enhance efficacy of immune checkpoint blockade therapy via promoting cross-presentation and modifying immune ...that PARP inhibitors could ...
12
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation
... The radiosensitizing effect of PARP inhibition in Res196 cells was measured using a clonogenic assay. To assess clonogenic survival, exponentially growing Res196 cells were trypsinized, plated in triplicate ...
13
NF- B signaling mediates acquired resistance after PARP inhibition
... with PARP inhibitors generates acquired resistance within these ...to PARP inhibitor by continuous treatment with the drug, and then used RNA sequencing to compare gene ...in PARP inhibitor- ...
15
Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition
... PAK1 inhibition in the genetic profile of breast cancer cells, nor did they use clinically relevant small molecule ...pharmacological inhibition of PAK in PAK1 overexpressing cells, compromises the ability ...
14
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
... The emergence of secondary mutations in BRCA1/2 germline mutation carriers has been previously described in case reports and small retrospective series of breast or ovarian cancer patients after PARP ...
34
PARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier
... [10]. PARP is re- sponsible for synthesis and transfer of ADP-ribose poly- mers to target proteins, regulation of DNA repair, and genomic integrity maintenance ...[11]. PARP hyperactivity has been found in ...
16
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
... and PARP inhibition, the first PARP inhibitor has been licensed (olaparib) for ovarian cancer patients with a BRCA ...potent PARP inhibitors are also in late phase clinical ...different ...
32
Biological Modulation of Parp Inhibition in Triple Negative Breast Cancer, a Combinational Approach Implementing Multitargeted Epigenetic Therapy (Mtet) with Parp Inhibition, in Advanced Breast Cancer: A Case Study
... of PARP inhibitors as active agents to inhibit the DNA re- pair was a revolution in the cancer therapeutics, however, such approach only has shown promising results for a short time in majority of cases due to ...
11
ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition
... Next, we asked whether ATM-depletion can sensitize MCF-7 cells to iniparib (BSI-201, SAR240550), a com- pound originally described as an irreversible inhibitor of PARP-1 [30], but recently shown to act as a ...
10
PARP inhibition in atherosclerosis and its effects on dendritic cells, T cells and auto-antibody levels
... The present study demon strates reduced numbers of D Cs in the adven- titia, located next to atherosclerotic lesions, but not in the plaque of IN0-1001 treated compared to co[r] ...
8
Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer
... through selection of preexisting subclones already pres- ent at diagnosis remains an area of keen interest and could influence the selection of NAC versus PDS. Furthermore, investigation into whether different mutation ...
13
PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1 deficient non–small cell lung cancer
... cGAS is a potent sensor of almost any form of cytoplasmic DNA. It can detect free DNA, arising from reverse transcription of endogenous retroviruses (55) or mitochondrial DNA instabil- ity (56); and micronuclei, which ...
19
PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma
... 7]. PARP inhibitors exhibit antitumour activity in part due to their ability to induce synthetic lethality in cells deficient for homologous recombination repair [8-12] and also in triple negative breast cancer ...
14
S-nitrosation on zinc finger motif of PARP-1 as a mechanism of DNA repair inhibition by arsenite
... through inhibition of DNA ...the inhibition of the DNA repair protein Poly(ADP-ribose) polymerase 1 ...the PARP-1 zinc finger DNA binding ...RNS-mediated PARP inhibition by arsenic ...
11
Poly(ADP ribose) polymerase as a novel regulator of 17β estradiol induced cell growth through a control of the estrogen receptor/IGF 1 receptor/PDZK1 axis
... that PARP-1 may control expression of a number of proteins by regulating their expression at the mRNA level or by influencing their sta- ...instance, PARP-1 regulates expression of sev- eral inflammatory ...
9
Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
... SA1 inhibition sensitizes SA2-mutated tumors to the treatment of PARP inhibitor ...and PARP inhibition, we investigated the efficacy of the combined treatment in SA2-mutated tumors in ...
16
Disrupted ADP ribose metabolism with nuclear Poly (ADP ribose) accumulation leads to different cell death pathways in presence of hydrogen peroxide in procyclic Trypanosoma brucei
... The real function of PARG regarding cell death is con- troversial and some authors have reported that PARG in- hibition provides protection to oxidative-stressed neuronal cells [47]. Studies based on PARG-silenced cells ...
15
PubMedCentral-PMC5077650.pdf
... of PARP was also measured as a common endpoint to see if the DNA repair ability was also ...cause PARP inhibition, which has been shown to result in increased DNA damage (Qin et ...in PARP ...
18
Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel
... According to treatment protocols established in BRCA mutated ovarian carcinomas we successfully applied combined chemotherapy of carboplatin, paclitaxel and the PARP1-inhibitor olaparib. Initially, we assumed a somatic ...
7